Ger­many's Evotec ex­pands in­to bi­o­log­ics with up to $90M deal for Seat­tle's Just Bio­ther­a­peu­tics

Ger­man drug dis­cov­ery com­pa­ny Evotec — which has a ro­bust rolodex of bio­phar­ma part­ners such as Bay­er, Boehringer In­gel­heim, Cel­gene, No­var­tis, No­vo Nordisk, Pfiz­er, Sanofi and …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER